Genzyme Campath study in multiple sclerosis meets co-primary endpoint

By Lisa Kerner

Charlotte, N.C., Sept. 14 - Genzyme Corp. said two-year interim results from its phase 2 trial showed that patients taking Campath (alemtuzumab) at high and low doses reported a 75% reduction in the risk of multiple sclerosis relapse compared to patients treated with Rebif (interferon beta-1a).

As a result, the trial met its first co-primary endpoint.

The phase 2 trial randomized 334 patients with active relapsing-remitting multiple sclerosis at 49 medical centers in Europe and the United States.

Genzyme had suspended dosing of alemtuzumab in September 2005 after three patients developed immune thrombocytopenic purpura. The trial remains on clinical hold in the United States, according to the Cambridge, Mass.-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.